INOGEN INC (INGN)
Sector: Health Care
2026 Annual Meeting Analysis
INOGEN INC · Meeting: June 5, 2026
Directors FOR
1
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Mr. Boehnlein has served since March 2022, meaning his tenure fully overlaps Inogen's severe stock underperformance: the stock fell 46.5% over three years while the company's own compensation peers gained a median of 21.4%, a gap of nearly 68 percentage points — well above the 20-point threshold our policy requires to vote against; the 5-year check provides no relief because the 5-year gap of -52.3pp also exceeds the 20pp threshold, confirming this is not a short-term blip.
For Analysis
Ms. Sahney joined the board in January 2025, which is less than 24 months before the June 2026 annual meeting, so she is exempt from the TSR underperformance trigger under our policy; she brings relevant medical device and commercial leadership experience appropriate for Inogen's industry.
Of the two Class III nominees, Mira Sahney receives a FOR vote because she joined within the 24-month new-director exemption window. Glenn Boehnlein receives an AGAINST vote because his tenure since March 2022 fully overlaps Inogen's severe stock underperformance — the company's shares lost 46.5% over three years while the named peer group gained a median of 21.4%, a gap of nearly 68 percentage points that far exceeds the 20-point policy threshold for companies with negative absolute TSR; the five-year record does not provide relief as the five-year gap also exceeds the threshold.
Say on Pay
✓ FORCEO
Kevin R.M. Smith
Total Comp
$2,613,804
Prior Support
N/A
CEO Kevin R.M. Smith received total compensation of approximately $2.6 million in 2025, which is within a reasonable range for a CEO at a roughly $200 million market-cap medical device company undergoing a turnaround — the pay level does not appear to exceed the 20% above-benchmark threshold that would require a No vote. The compensation program includes performance-based equity awards, which is consistent with the policy's requirement that a meaningful portion of pay be variable and tied to outcomes. Although Inogen's stock has significantly underperformed its peers, Mr. Smith joined as CEO only in November 2023 and has been leading a turnaround that returned the company to positive adjusted EBITDA in 2025, providing some justification for incentive compensation during his early tenure.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
N/A
Audit Fees
$1,574,000
Non-Audit Fees
$1,900
Non-audit fees in 2025 were just $1,900 against audit fees of $1,574,000 — a ratio of roughly 0.1%, far below the 50% threshold that would raise independence concerns; Deloitte is a Big 4 firm appropriate for a public company; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire under our policy, and the absence of disclosed tenure is noted as a minor negative but does not change the vote.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 5
Approval of an Amendment to Our Charter to Declassify Our Board of Directors
This is a board-proposed charter amendment to phase out the classified board structure and move to annual elections for all directors, which is a well-established governance improvement that increases director accountability by letting shareholders vote on every director every year. The board is proposing this directly in response to stockholder feedback, and while the phase-in means existing directors serve out their current terms before the full switch takes effect in 2029, the direction of change is clearly pro-shareholder. Under our policy, improvements from a classified structure to annual elections should be supported even if the transition is not instantaneous.
Overall Assessment
Inogen's 2026 annual meeting ballot presents five proposals across director elections, auditor ratification, say-on-pay, an equity plan share increase, and a board-initiated charter amendment to declassify the board. The most significant governance concern is the company's severe multi-year stock underperformance — shares lost 46.5% over three years while the named peer group gained a median of 21.4% — which drives an AGAINST vote for Audit Committee Chair Glenn Boehnlein, whose full tenure overlaps this underperformance period; the remaining proposals receive FOR votes, including the declassification charter amendment which is a meaningful pro-shareholder governance improvement made in direct response to stockholder pressure.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing